© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri/File Photo
(Reuters) – Pfizer Inc (NYSE:) on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany’s BioNTech to $33.5 billion from $26 billion, the second increase this year in the face of a global scramble for the shots.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.